Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Servier
Eli Lilly and Company
Turning Point Therapeutics, Inc.
Sotio Biotech Inc.
Pfizer
Pfizer
FindCure Biosciences (ZhongShan) Co., Ltd.
Eisai Inc.
Erasca, Inc.
Arvinas Inc.
Solve Therapeutics
Eli Lilly and Company
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Degron Therapeutics Co.
Bayer
Actym Therapeutics, Inc.
Sanofi
Exelixis
Sanofi
Merck Sharp & Dohme LLC
Ikena Oncology
Eli Lilly and Company
Exelixis
Sensei Biotherapeutics, Inc.
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Alume Biosciences, Inc.
Eli Lilly and Company
Theratechnologies
Xynomic Pharmaceuticals, Inc.
Salubris Biotherapeutics Inc
NantCell, Inc.
Kura Oncology, Inc.
Turning Point Therapeutics, Inc.
ABM Therapeutics Corporation
TransThera Sciences (Nanjing), Inc.
Sanofi
Hoffmann-La Roche
Genmab
Kineta Inc.
Eisai Inc.
DualityBio Inc.
Blue Note Therapeutics
MacroGenics
Eisai Inc.
Eisai Inc.
Exelixis